The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.
The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.
复制标题
多巴胺 D2 受体基因启动子区的 -141C Ins/Del 多态性与精神分裂症患者接受多巴胺拮抗剂治疗期间的抗焦虑和抗抑郁作用相关。
DOI：
10.1097/00008571-200108000-00009
复制
发表时间：
2001
期刊：
影响因子：
--
通讯作者：
K. Otani
中科院分区：
文献类型：
--
作者：
A. Suzuki;T. Kondo;K. Mihara;N. Yasui‐Furukori;M. Ishida;H. Furukori;S. Kaneko;Y. Inoue;K. Otani
以往的研究表明，多巴胺D2受体（DRD 2）基因启动子区的-141 C Ins/Del多态性的无Del等位基因的受试者比有一个或两个Del等位基因的受试者的DRD 2密度低。本研究旨在探讨DRD 2启动子-141C Ins/Del多态性是否与选择性DRD 2拮抗剂治疗精神分裂症的疗效相关。受试者包括49例接受溴哌利多（30例，平均剂量+/- SD：11.4 +/- 4.8 mg/d）或奈莫必利（19例，18 mg/d）治疗的急性加重精神分裂症住院患者。治疗前及治疗后3周采用简明精神病评定量表（BPRS）评定临床症状。采用聚合酶链反应（PCR）方法检测-141C Ins/Del DRD 2基因型，即Ins和Del等位基因。35例患者为Ins等位基因纯合子，14例为Del和Ins等位基因杂合子。治疗3周后，无Del等位基因的患者焦虑抑郁症状改善的百分比高于有Del等位基因的患者（58.5 ± 44.5%对24.1 ± 48.2%），而两个基因型组之间总BPRS或其他亚组症状（阳性、阴性、兴奋和认知症状）改善的百分比相似。目前的研究结果表明，-141C的Ins/Del DRD 2多态性与精神分裂症患者的抗焦虑和抗抑郁治疗的效果。
Previous studies have demonstrated a lower density of dopamine D2 receptor (DRD2) in subjects without Del alleles of the -141C Ins/Del polymorphism in DRD2 gene promoter region than in those with one or two Del alleles. The present study aimed to examine whether the -141C Ins/Del DRD2 promoter polymorphism is related to therapeutic response to selective DRD2 antagonists in the treatment of schizophrenia. Subjects consisted of 49 acutely exacerbated schizophrenic inpatients treated with bromperidol (30 cases, mean dose +/- SD: 11.4 +/- 4.8 mg/day) or nemonapride (19 cases, 18 mg/day). Clinical symptoms were evaluated by the Brief Psychiatric Rating Scale (BPRS) before and 3 weeks after the treatment. The -141C Ins/Del DRD2 genotypes, the Ins and Del alleles, were determined by a polymerase chain reaction method. Thirty-five patients were homozygous for the Ins allele and 14 were heterozygous for the Del and Ins alleles. The patients without Del allele showed a higher percentage of improvement in anxiety-depression symptoms than those with Del allele (58.5 +/- 44.5% versus 24.1 +/- 48.2%) after 3 weeks of treatment while percentage improvement in total BPRS or other subgrouped symptoms (positive, negative, excitement and cognitive symptoms) was similar between the two genotype groups. The present results suggest that the -141C Ins/Del DRD2 polymorphism is associated with anxiolytic and antidepressive effects of neuroleptic treatment in schizophrenic patients.
首发精神分裂症的抑郁症。
DOI：
10.1176/ajp.150.11.1643
发表时间：
1993
期刊：
The American journal of psychiatry
影响因子：
--
作者：
Koreen,AR;Siris,SG;Chakos,M;Alvir,J;Mayerhoff,D;Lieberman,J
通讯作者：
Lieberman,J